4 Results for "

17-AAG

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "17-AAG" in MCE Product Catalog:

70
70 Cited Publications
Cat. No.: HY-10211
CAS No.: 75747-14-7
Purity:  99.01%
Synonyms: 17-AAG; NSC 330507; CP 127374
Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-124653
CAS No.: 2133499-85-9
Purity:  99.70%
Synonyms: J2
Target:  

HSP

Research Areas:  

Cancer

HSP27 inhibitor J2 (J2) is a HSP27 inhibitor, which significantly induces abnormal HSP27 dimer formation and inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function thereof. HSP27 inhibitor J2 (J2) remarkably enhances the antiproliferative activity of 17-AAG and sensitizes cisplatin-induced lung cancer cell growth inhibition .
loading...
    loading...
Cat. No.: HY-10211R
CAS No.: 75747-14-7
Synonyms: 17-AAG (Standard); NSC 330507 (Standard); CP 127374 (Standard)
Tanespimycin (Standard) is the analytical standard of Tanespimycin. This product is intended for research and analytical applications. Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .
loading...
    loading...
Cat. No.: HY-10211S
Synonyms: 17-AAG-d5; NSC 330507-d5; CP 127374-d5
Tanespimycin-d5 (17-AAG-d5; NSC 330507-d5; CP 127374-d5) is the deuterium labeled Tanespimycin (HY-10211). Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .
loading...
    loading...